Diabetes Research and Clinical Practice - Volume 120 - Supplement 1 - October 2016

142 / 244

using the paired t-test. We also examined if the changes in the
HbA1c and body weight differed between ethnic groups by
gender (males vs females), DM duration (<10 years vs ≥ 10
years) and age (<50 years and ≥50 years) using linear mixed
models.
Results: We enrolled 196 (57.1%) Chinese, 70 (20.4%) Malay and
77 (22.4%) Indians. The mean age (SD) of Chinese, Malays and
Indians were 59.14 (14.72) years, 56.57 (12.61) years and 56.00
(13.63) years respectively (p = 0.001). The mean duration of
DM was 14.02 (9.28) years for Chinese, 13.52 (8.51) years for
Malays and 11.03 (7.62) years for Indians (p < 0.001). HbA1c
improved at the end of 12 months of follow-up for all three
ethnic groups (Chinese, Δ-0.43%, p = 0.036; Malays, Δ0.66%,
p = 0.0867; Indians, Δ0.54%, p = 0.088). The interaction term
ethnicity*follow-up was not statistically significant. There
were no statistically significant changes in the body weight
for all the three ethnic groups at the end of the 12-month
follow-up. Patients who were older than 50 years old had more
sustained HbA1c response over the 12-month follow-up
compared to patients less than 50 years old. The change in
the HbA1c was similar for both genders, and for those with
duration of diabetes <10 years and 10 years or more.
Conclusions: A 12-month treatment regimen with DPP-IV
inhibitor improves HbA1c similarly in all three Asian ethnic
groups with T2DM. The improvement in the HbA1c is more
sustained for those patients older than 50 years. Ethnicity,
gender, and duration of diabetes do not modify the efficacy of
DPP-IV inhibitor treatment in this Asian population.
PD-104
Effectiveness of the personalized manager service on
postprandial blood glucose management in Taiwanese
patients with diabetes
Meng-Yu LIN 1, Ching-Li LIN2, Frances Chang MA 1,4,
Shih-Tzer TSAI 1,3*. 1Department of Nutritional Therapy, Cheng-
Hsin General Hospital, 2Department of Nursing, Cheng-Hsin General
Hospital, 3Department of Internal Medicine, Cheng-Hsin General
Hospital, 4Enjoy Foods Nutrition Center, Taiwan
Optimizing glycemic control is an important homework for
people with diabetes (PWD). According to the AADE7 Self-Care
Behaviors ™ model, fulfilling healthy eating, physical activ-
ities, structured monitoring, and taking medications regularly
are crucial to achieve and maintain metabolic goals.
The aim of this survey was to assess the effectiveness of
personalized care by using the platform integrating self-
monitoring, dietary management, exercise, medication
records along with the engagement of health care team on-
and-off line consultation.
From June 2015 to December 2015, voluntary participants
were provided with personalized care service software
(Health2Sync), downloading to smartphones, uploading
demographics, blood glucose measurements, diet, exercise
and medication records by PWD for at least 12 weeks.
Participants could undergo consultations through a built-in
features with certified diabetes educators (CDEs) during the
period.
Eleven patients, 4 T1DM (aged 30.3 ± 8.3 years, duration 21 ± 7.8
years, baseline A1C 8.0 ± 1.3%) and 7 T2DM (aged 50.1 ± 14.5
years, duration 10.3 ± 11.9 years, baseline A1C 7.6 ± 1.3%) were
enrolled. They monitored their blood glucose for 165.6 ± 153.2
times, executed food records for 18.4 ± 20.7 times and inter-
acted with health care team for 34.5 ± 64.3 times in 12 weeks.
Both their mean fasting and postprandial blood glucose levels
showed a decline trend from 123.4 ± 42.1 and 153.9 ± 65.3 mg/
dL at baseline to 119.2 ± 34 and 140.1 ± 35.1 mg/dL at 12 weeks,
respectively. The rate of goal attainment for given postprandial
glucose increased from 65.2% to 76.4% (p < 0.05) over the
observation period.
The implementation of personalized care platform, and the
involvement of on-and-off line CDE consultation, can improve
postprandial glycemic control in short-term. We hope in the
future the application of this working model could overcome
the barriers of patient accessibility of self-management
education/support, empower the PWD and enhance their
performance in metabolic control.
PD-105
The clinical effect of dapaglifrozin in type 2 diabetics with
obesity: Retrospective analysis in a real practice setting
Youngju CHOI1, Kapbum HUH 1*. 1Huh’s Diabetes Center, Korea
Background: A limitation with randomized controlled trials
is that, while they provide unbiased evidence of the efficacy
of interventions, they do so under unreal conditions and in a
very limited and highly selected patient population. Our aim
was to provide data about the effectiveness of dapaglifrozin
treatment in a real-world and clinical practice setting.
Methods:In a retrospective and observational study, data from
210 patients (mean age: 53 ± 9 yr, male 47%) with a minimum 6
months of dapaglifrozin therapy were analyzed, who visited
Huh’s Diabetes Center from Jan. 2015 to Dec. 2015, who gave
complete information on all covariates.
Insulin sensitivity was directly assessed by short insulin
tolerance test as a rate constant for plasma glucose disappear-
ance (kitt, %/min) after intravenous injection of regular insulin
(0.1 U/kg).
Results: Mean baseline glycated hemoglobin (HbA1c) was 8.4 ±
1.2% and mean body mass index (BMI) was 28.3 ± 3.3 kg/m2.
After 6 months of treatment with dapaglifrozin, we observed
a change in HbA1c of −1.2 ± 0.9%, −2.9 ± 2.4 kg in weight
and −1.1 ± 0.9 kg/m(2) in BMI (p < 0.001 for all). Compared to
baseline, there was a significant reduction in systolic blood
pressure (−7.4 mmHg, p < 0.001), LDL cholesterol (− 5.7 mg/dL,
p = 0.005) and triglycerides (−24.3 mg/dL, p < 0.001). In
patients treated with dapaglifrozin as an add-on therapy, a
decrease of − 1.4% in HbA1c (p < 0.001) and a weight reduc-
tion of −2.8 kg (p < 0.001) were observed. In patients swit-
ched from other antidiabetic drug, dapaglifrozin induced a
decrease of −1.1% in HbA1c (p < 0.001) and a reduction in
weight (−2.9 kg, p < 0.001). The difference of efficacy was not
noted according to the baseline characteristics (age, sex, BMI,
c-peptide and kitt).
Conclusion: Our study confirms the effectiveness of dapagli-
frozin in a real-life and clinical practice setting.
PD-106
Comparison of short-and long-acting glucagon-like peptide 1
receptor agonists on postprandial glucose excursion, insulin
and glucagon secretions and gastric emptying
Hitoshi KUWATA1,2*, Daisuke YABE2,3 , Takeru NAGATA1 ,
Sodai KUBOTA1, Saki OKAMOTO1, Shinji UENO1,
Yui SAKURAMACHI1, Koin WATANABE1 , Takanori HYO1,
Nagaaki TANAKA1, Yoshiyuki HAMAMOTO1,2,
Takeshi KUROSE1,2, Yutaka SEINO1,2. 1Center for Diabetes,
Endocrinology and Metabolism, Kansai Electric Power Hospital,
2Kansai Electric Power Medical Research Institute, 3Department of
Diabetes, Endocrinology and Nutrition, Kyoto University Graduate
School of Medicine, Japan
Background and aims: Glucagon-like peptide-1 receptor ago-
nists (GLP1-RAs) are classified into short- and long-acting
agents according to their pharmacokinetic differences. It has
been suggested that short-acting and long-acting agents exert
different actions on insulin and glucagon secretions as well as
on gastric emptying, which results in different outcomes of
glycemic control. However, alterations in insulin and glucagon
secretions and gastric emptying and their contributions to
glycaemia in response to short- and long-acting agents have
not been fully evaluated.
Materials and methods: We performed meal tolerance test
before and 12 weeks after initiation of the long-acting GLP-1RA
Poster Presentations / Diabetes Research and Clinical Practice 120S1 (2016) S65–S211 S124